The US Food and Drug Administration on Sunday issued an emergency use authorization for convalescent plasma for the treatment of Covid-19 in hospitalized patients.
The agency said it concluded that the product may be effective in treating Covid-19 and that "the known and potential benefits of the product outweigh the known and potential risks of the product."
President Donald Trump is expected to discuss the announcement during a Sunday media briefing.
Convalescent plasma is created from the blood of people who have recovered from Covid-19, and it has shown some success in two other deadly coronaviruses: MERS and SARS. It has also been used to treat flu and Ebola.
Emergency use authorization from the FDA does not require the same level of evidence as full FDA approval. At the end of March, the FDA created a pathway for scientists to try convalescent plasma with patients and study its impact.
Physicians have been using the treatment since. So far, more than 60,000 people in the United States have been treated with convalescent plasma.